ImmuPharma plc (LON:IMM – Get Free Report) fell 14.7% during mid-day trading on Monday . The stock traded as low as GBX 3.40 and last traded at GBX 3.40. Approximately 1,369,060 shares traded hands during mid-day trading, a decline of 46% from the average session volume of 2,540,783 shares. The stock had previously closed at GBX 3.99.
ImmuPharma Price Performance
The firm has a 50-day simple moving average of GBX 4.01 and a 200 day simple moving average of GBX 4.94. The company has a market capitalization of £21.24 million, a PE ratio of -9.20 and a beta of 3.01.
ImmuPharma (LON:IMM – Get Free Report) last issued its earnings results on Wednesday, May 27th. The company reported GBX (0.37) earnings per share for the quarter. ImmuPharma had a negative return on equity of 353.21% and a net margin of 3,519.56%. Equities research analysts expect that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Stories
- Five stocks we like better than ImmuPharma
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
- If Boeing Ramps Up Production, These Suppliers May Win Big
- Marvell Takes a Shot a Broadcom’s Throne With Google Deal
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
